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Abstract:	
Background	
Glioblastoma	(GBM)	is	the	most	common	malignant	brain	cancer	occurring	in	
adults,	and	is	associated	with	dismal	outcome	and	few	therapeutic	options.	GBM	
has	been	shown	to	predominantly	disrupt	three	core	pathways	through	somatic	
aberrations,	rendering	it	ideal	for	precision	medicine	approaches.	
	
Methods	
We	describe	a	35	year‐old	female	patient	with	recurrent	GBM	following	surgical	
removal	of	the	primary	tumor,	adjuvant	treatment	with	temozolomide,	and	a	3‐
year	disease‐free	period.	Rapid	whole	genome	sequencing	(WGS)	of	three	
separate	tumour	regions	at	recurrence	was	performed	and	interpreted	relative	
to	WGS	of	two	regions	of	the	primary	tumour.	
	
Results	
We	found	extensive	mutational	and	copy	number	heterogeneity	within	the	
primary	tumour.	We	identified	a	TP53	mutation	and	two	focal	amplifications	
involving	PDGFRA,	KIT	and	CDK4,	on	chromosomes	4	and	12.	A	clonal	IDH1	
R132H	mutation	in	the	primary,	a	known	GBM	driver	event,	was	detectable	at	
only	very	low	frequency	in	the	recurrent	tumour.	After	subclonal	diversification,	
evidence	was	found	for	a	whole	genome‐doubling	event	and	a	translocation	
between	the	amplified	regions	of	PDGFRA,	KIT	and	CDK4,	encoded	within	a	
double	minute	chromosome	also	incorporating	miR26a‐2.	The	WGS	analysis	
uncovered	progressive	evolution	of	the	double	minute	chromosome	converging	
on	the	KIT/PDGFRA/PI3K/mTOR	axis,	superseding	the	IDH1	mutation	in	
dominance	in	a	mutually	exclusive	manner	at	recurrence,	consequently	the	
patient	was	treated	with	imatinib.	Despite	rapid	sequencing	and	cancer‐genome	
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3	
guided	therapy	against	amplified	oncogenes,	the	disease	progressed,	and	the	
patient	died	shortly	after.		
	
Conclusions	
This	case	sheds	light	on	the	dynamic	evolution	of	a	GBM	tumor,	defining	the	
origins	of	the	lethal	subclone,	the	macroevolutionary	genomic	events	dominating	
the	disease	at	recurrence	and	the	loss	of	a	clonal	driver.	Even	in	the	era	of	rapid	
WGS	analysis,	cases	such	as	this	illustrate	the	significant	hurdles	for	precision	
medicine	success.		
	
	
Keywords:	
Glioblastoma,	multiregion	sequencing,	intratumour	heterogeneity,	double	
minute	
	
Key Message: "In a glioblastoma tumour with multiregion sequencing before and 
after recurrence, we find an IDH1 mutation that is clonal in the primary but lost at 
recurrence. We also describe the evolution of a double minute chromosome 
encoding regulators of the PI3K signaling axis that dominates at recurrence, 
highlighting the challenges of an evolving and dynamic oncogenic landscape for 
precision medicine." 
 by guest on M
arch 11, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
4	
Introduction		
Glioblastoma	(GBM)	is	the	most	common	malignant	brain	cancer	occurring	in	
adults	and	is	associated	with	poor	prognosis	and	a	median	overall	survival	of	
only	15	months[1].	Nearly	all	GBM	tumours	recur	after	surgery,	radiotherapy	
and	chemotherapy,	with	a	median	time	to	recurrence	of	7	months[1].		
	
Accumulating	evidence	suggests	that	treatment	failure	in	cancer	may	be	driven	
by	intratumour	heterogeneity	(ITH)	and	branched	tumour	evolution	involving	
genetically	distinct	subclones[2].	Recent	studies	have	documented	widespread	
ITH	in	GBM.	Sottoriva	et	al[3]	found	that	each	individual	tumour	can	harbour	
multiple	distinct	copy‐number	profiles	and	transcriptomic	subtypes	
simultaneously.	Johnson	et	al[2]	revealed	spatial	and	temporal	heterogeneity	in	
GBM,	confirmed	the	importance	of	TP53	and	IDH1	as	early	driver	mutations[4,	
5],	and	demonstrated	the	impact	of	temozolomide	(TMZ)	treatment	on	tumour	
evolution,	with	6	of	10	tumours	showing	evidence	of	TMZ‐induced	
hypermutation	at	recurrence.		
	
In	order	to	fully	assess	ITH	within	the	life‐history	of	a	single	tumour	and	attempt	
to	offer	the	patient	a	cancer	genome‐guided	therapy,	we	implemented	rapid	
multi‐region	whole‐genome	sequencing	(WGS)	in	a	patient	with	recurrent	GBM.	
This	analysis	reveals	the	temporal	and	spatial	evolution	of	a	GBM	tumour,	
defining	the	origins	of	the	lethal	subclone	from	a	subclone	in	the	primary	tumour	
and	the	associated	macroevolutionary	genomic	events	dominating	the	disease	at	
recurrence,	confounding	treatment	success.		
	
Methods	
Ethics	
Written	informed	consent	was	obtained	from	the	patient	in	the	Hospitaux	
Universitaires	de	Geneve	“Analyse	de	la	reponse	immunologique	contre	les	
tumeurs	cerebrales”	translational	approved	protocol	IRB	03‐126.	Tumour	
material	was	analysed	under	the	UCL‐Cancer	Institute	and	Pathology	biobank	
(UCLHRTB	10/H1306/42).	The	patient	provided	written	informed	consent	to	
tumour	sequencing	analysis	within	a	compassionate	setting.	The	study	was	
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5	
conducted	according	to	the	provisions	of	the	Declaration	of	Helsinki	and	the	
Good	Clinical	Practice	Guidelines	of	the	International	Conference	on	
Harmonization.	
	
WGS	data	processing	and	analysis	
WGS	was	performed	by	Illumina,	UK.	Mutation	calling	and	filtering	was	
performed	using	VarScan2	as	described	[6],	annotation	of	coding	mutations	were	
performed	using	ANNOVAR[7].	Structural	variant	(SV)	breakpoint	mechanism	
classification	was	performed	according	to	the	criteria	defined	in	Yang	et	al[8].	
Reconstruction	of	the	putative	double	minute	chromosomes	was	performed	as	
described	in	Sanborn	et	al[9]	and	breakpoints	mapping	to	the	focal	
amplifications	were	validated	by	PCR	and	Sanger	Sequencing.	Copy	number	
variation	(CNV)	analysis	was	performed	on	the	WGS	data.	Purity,	ploidy	and	
allele‐specific	copy	number	estimates	were	obtained	with	Sequenza	[10].	Clonal	
analysis	was	performed	as	described	in	Bolli	et	al	[11],	estimating	the	cancer	
cell	fraction	(CCF)	by	integrating	variant	allele	frequency	estimates	with	copy	
number,	purity	and	ploidy	estimates.	Single	sample	and	multi‐sample	Dirichlet	
process	clustering	was	performed	using	the	DPpackage		R	package[12].	In	this	
work,	mutations	are	referred	to	as	“subclonal”	if	their	CCF	indicates	they	are	
present	in	only	a	subset	of	cancer	cells	within	a	given	sample	(CCF	<	1).	
Mutations	present	in	all	cancer	cells	of	a	given	sample	(CCF	=	1)	are	referred	to	
as	“clonal”.	Genome	doubling	was	determined	from	the	comparison	of	the	
sequencing	of	the	grade	II	and	the	grade	IV	regions	and	by	considering	the	
mutations	located	in	the	portion	of	the	genome	where	a	clear	doubling	of	the	
number	of	alleles	was	detected,	see	Supplementary	Information	for	details.	All	
data	analysis	was	performed	in	R	version	3.0.2,	all	p‐values	are	two‐sided.	
	
Results	
Clinical	case	report		
A	35‐year‐old	female	presented	with	partial	complex	seizures	in	January	2007,	
increasing	in	frequency	after	the	delivery	of	her	second	child	in	September	2007	
(Figure	1A).	MRI	carried	out	in	June	2008,	revealed	a	right	temporal	mass	
(6x6.7x4.5	cm)	with	slight	contrast	enhancement.	She	underwent	complete	
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6	
removal	of	the	tumour	on	July	3rd,	2008	and	the	diagnosis	of	WHO	grade	IV	
astrocytoma	(GBM)	was	established	(the	tumour	consisted	of	a	grade	II	and	
grade	IV	histological	components).	She	received	concomitant	treatment	with	
irradiation	(60	Gy	in	30	fractions)	and	TMZ,	followed	by	6	monthly	cycles	of	TMZ	
(200	mg/m2	D1‐D5)	until	March	2009.	She	was	free	of	symptoms	for	two	years	
but	partial	seizures	reappeared	in	early	2011.	A	further	MRI	showed	a	multifocal	
recurrence	in	the	right	temporal	area	extending	to	the	thalamus	and	the	corpus	
callosum.	Considering	the	long	disease	free	interval	(3	years)	between	first	
treatment	and	recurrence,	TMZ	at	a	similar	dose	and	schedule	was	prescribed	
again.		
	
In	March	2012,	she	presented	with	acute	headache	and	intracranial	
hypertension.	MRI	showed	massive	progression	mainly	in	the	right	frontal	area	
with	risk	of	herniation.	She	underwent	partial	removal	of	the	tumour	on	March	
29th,	2012.	The	histology	confirmed	grade	IV	astrocytoma	with	MGMT	gene	
promoter	methylation.	She	received	bevacizumab	and	TMZ;	after	transient	
clinical	improvement,	her	clinical	condition	deteriorated	and	TMZ	was	replaced	
by	800mg	imatinib	daily,	guided	by	the	WGS	data,	sequenced	and	reported	
within	7	days	by	Illumina,	indicating	amplification	of	KIT	and	PDGFRA.	The	
tumour	progressed	rapidly	on	therapy	and	she	died	3	months	after	the	2nd	
surgical	debulking	procedure.	
	
Whole	genome	sequencing		
Archival	formalin	fixed	paraffin	embedded	(FFPE)	specimens	of	the	grade	II	and	
IV	primary	samples	along	with	three	fresh‐frozen	samples	from	the	recurrence	
and	a	germline	reference	were	WGS	to	a	depth	of	30X	(~1.3	x	106	paired	reads	
per	sample;	Table	S1	in	Supplementary	Information).	The	three	recurrence	
regions	were	homogeneous	at	the	SNV	level	indicating	limited	clonal	variation	in	
the	recurrence,	however	the	SNV	calling	was	hampered	by	stromal	
contamination	(Table	S1).	The	3	recurrent	regions,	referred	to	as	A1,	A2	and	A3,	
respectively,	were	merged	in	silico	in	a	single	alignment	file,	termed	As,	to	
increase	the	resolution	and	improve	the	capacity	to	define	the	evolutionary	
trajectory	of	the	recurrence	specimen.	1271	and	1935	high‐confidence	somatic	
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7	
silent	and	non‐silent	SNVs	were	identified	in	the	grade	II	and	IV	regions	
respectively,	and	1435	in	the	recurrence	specimen.	When	comparing	the	grade	II	
and	grade	IV	to	the	recurrence,	the	grade	IV	shared	338	mutations	with	the	
recurrence	not	found	in	the	grade	II	region,	while	the	grade	II	only	shared	1	
mutation	with	the	recurrence	not	found	in	the	grade	IV	region	(Figure	1B,	coding	
mutations	only	in	Figure	S1,	detailed	mutation	information	in	Supplementary	
File).	Given	that	the	grade	II	region	exhibited	fewer	private	mutations	(69/1271,	
Figure	1B,	1C),	this	indicates	it	most	closely	resembles	the	most	recent	common	
ancestor	(MRCA),	and	that	the	recurrence	specimen	evolved	from	the	grade	IV	
region.		
	
Extensive	mutational	variation	found	between	grade	II	and	grade	IV	
regions		
Several	clonal	mutations	were	found	in	both	primary	lesions	suggesting	a	shared	
clonal	origin.	These	include	a	TP53	Y220C	mutation,	a	frame	shift	mutation	in	
ATRX	(K1871fs),	and	an	IDH1	mutation,	R132H.	These	genes	have	previously	
been	described	as	driver	events	for	GBM[4,	13],	and	ATRX	mutations	has	been	
shown	to	co‐occur	with	TP53	and	IDH1	mutations	[2],	and	to	be	a	driver	of	
alternative	telomere	lengthening[14].	Clustering	the	mutation	CCFs	in	the	grade	
II	grade	IV	regions	revealed	six	distinct	clusters	(Figure	1D).	Most	mutations	
were	identified	as	clonal	in	both	primary	lesions	or	as	clonal	in	one	but	missing	
from	the	other	(clusters	1,	3	and	6).	However,	we	also	found	202	mutations	that	
were	clonal	in	the	grade	IV	but	subclonal	in	the	grade	II	(cluster	2),	and	two	
clusters	of	mutations	(4	and	5)	that	were	subclonal	in	the	grade	IV	and	absent	in	
the	grade	II.	The	cluster	2	mutations	likely	represent	a	persistent	subclone	
within	the	grade	II	region	that	gave	rise	to	the	grade	IV	region,	while	clusters	4	
and	5	may	have	arisen	independently	in	the	grade	IV,	consistent	with	further	
subclonal	evolution	occuring	during	disease	progression.		
	
Primary	tumour	shows	heterogeneous	acquisition	of	copy	number	changes		
CNV	and	SV	analyses	identified	a	number	of	shared	events	in	the	primary	regions	
(Supplementary	Table	S2),	including	copy‐neutral	loss	of	heterozygosity	(LOH)	
on	chromosome	17p	following	TP53	mutation	(Figure	S2	A‐B);	CDK6	and	MET	
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8	
amplification	via	gain	of	7q;	and	two	high	level	focal	amplifications	(Figure	S3)	of	
4q12	(encoding	PDGFRA	and	KIT)	and	12q13.3‐q14.1	(encoding	CDK4,	AVIL	and	
miR‐26a‐2).	
	
ITH	was	also	detected	by	CNV	and	SV	analyses	(Figure	S4):	CDKN2A/B	loss	and	
other	CNVs	(gain	of	6p,	19p	and	20p;	loss	of	10q,	12q,	13,	16q,	17q	and	22)	were	
detected	only	in	the	grade	IV	sample.	Furthermore,	the	4q12	and	12q13.3‐14.1	
focal	amplifications	were	linked	by	numerous	translocations	in	the	grade	IV	but	
not	in	the	grade	II	sample	(Figure	S5,	Figure	S6).		
	
Allele‐specific	CNV	analysis	revealed	that	the	grade	IV	region	was	predominantly	
tetraploid,	while	the	grade	II	region	was	largely	diploid.	Mutations	in	the	grade	
IV	region	also	exhibited	a	bimodal	variant	allele	frequency	distribution	
consistent	with	a	genome‐doubling	(GD)	event,	exclusively	in	the	grade	IV	region	
(Figure	S7).		As	previously	reported	[15],	GD	is	permissive	for	chromosome	
instability	(CIN)	and	accelerated	cancer	genome	evolution.	Consistent	with	a	GD	
event	in	the	grade	IV	region	followed	by	chromosome	losses	due	to	increasing	
CIN[15],	flow	cytometry	on	the	fresh	tissue	of	the	three	recurrence	samples,	
revealed	a	DNA‐index	of	1.60,	1.58	and	1.55	for	each	recurrence	region	(Figure	
S8).		
	
Chromosome	4	rearrangements	and	evolution	of	a	double	minute	
chromosome	
Copy‐number	analysis	of	the	recurrence	tumour	revealed	focal	amplifications	in	
4q12	and	12q13.3‐q14.1	detected	in	the	grade	IV	region,	with	comparably	high	
copy	number	and	seemingly	identical	breakpoints	(Figure	S2C‐D,	Figure	S6).	
Although	the	grade	II	sample	also	shared	the	12q13.3‐q14.1	amplification,	the	
entire	4q‐arm	was	amplified	in	this	sample.	Structural	variant	analysis	revealed	
complex	chromosomal	re‐arrangements	linking	the	4q12	and	12q13.3‐q14.1	
focal	amplifications	in	the	higher‐grade	samples	only.	Taken	together,	these	
features	are	reminiscent	of	a	double	minute	chromosome,	a	relatively	frequent	
cytogenetic	event	in	GBM[9,	16].		
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To	investigate	this	further,	we	employed	a	precise	amplicon	reconstruction	
method[9].	This	involved	the	identification	of	breakpoints	related	to	the	highly	
amplified	regions,	followed	by	the	construction	of	a	breakpoint	graph	that	links	
the	amplified	segments	and	their	associated	breakpoints,	and	a	final	search	for	
an	optimal	path	that	completely	traverses	the	graph	(Figure	S9).	In	the	final	
solution,	segment	traversal	number	correlates	with	observed	relative	copy‐
number	of	the	segment,	and	circular	paths	are	indicative	of	a	double	minute	
chromosome.	
Consistent	with	a	double	minute	chromosome,	the	4q12	and	12q13.3‐q14.1	
amplifications	revealed	circular	paths,	indicating	double	minute	chromosomes	in	
the	grade	IV	and	recurrence	samples	(Figure	2A‐B	&	S9A).	Two	chromosomal	
intervals	(Figure	2A)	replete	with	putative	driver	genes	(PDGFRA,	KIT,	CDK4,	
AVIL	and	miR‐26a‐2)	are	re‐configured	into	circular	assemblies.	Figure	2B	
illustrates	the	optimal	paths	that	account	for	the	observed	breakpoints	and	high	
copy‐number	amplifications.	The	absence	of	this	structure	in	the	grade	II	sample	
suggests	that	the	12q13.3‐q14.1	focal	amplification	preceded	DM	formation,	
consistent	with	a	breakage‐bridge	fusion	cycle[17].	However,	L1	elements	flank	
the	12q13.3‐q14.1	amplification	(data	not	shown),	precluding	further	local	SV	
resolution.	There	are	numerous	precisely	shared	breakpoints	between	the	
double	minute	models,	and	all	breakpoints	tested	validated	(Figure	2C	&	S10),	
which	suggests	a	common	origin	of	the	extra‐chromosomal	structures.	
Moreover,	the	breakpoints	exhibit	features	of	non‐homologous	end‐joining[8]	
which	may	be	indicative	of	a	single	chromothriptic	event[18].		
To	investigate	the	origin	of	the	DMs,	we	performed	haplotype	analysis	in	the	
grade	IV	and	recurrence	DMs.	This	was	achieved	using	allele	frequencies	of	
heterozygous	SNPs	located	in	the	DM	locus	(Supplementary	Information).	
Consistent	with	a	shared	origin	of	the	DMs,	the	allelic	composition	of	the	DM	
haplotypes	appears	to	be	identical	at	the	4q12	and	12q13.3‐q14.1	loci	(Figure	
S11).	Moreover,	the	DM	derived	from	both	higher	copy‐number	haplotypes;	
conversely,	the	higher	copy‐number	haplotypes	on	4q12	were	predominantly	
lost	in	the	segments	flanking	the	DM.	Such	a	pattern	is	consistent	with	shattering	
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10	
of	a	“gained”	chromosome	4q	followed	by	“rescue”	of	oncogenic	fragments	
within	the	DM	and	loss	of	the	remainder	of	the	chromosome.	
Double‐minute	chromosome	is	associated	with	progression		
We	computed	a	distance	matrix	from	all	the	mutations	detected	in	the	primary	
regions	and	in	the	three	recurrence	regions,	establishing	a	phylogenetic	
relationship	between	the	sequenced	regions.	This	confirmed	that	the	recurrence	
specimen	was	most	similar	to	the	grade	IV	region,	with	the	DM	likely	arising	
between	the	grade	II	and	grade	IV	regions	(Figure	3A).	The	DM	carries	the	
putative	GBM	driver	gene	AVIL[19],	with	a	mutation	restricted	to	the	grade	
IV/recurrence	lineage	and	linked	to	the	focal	amplification	via	discordant	paired‐
end	reads	as	well	as	exhibiting	a	high	variant	allele	frequency	(chr12:58204830;	
Figure	S2F).	Additionally,	the	DM	unifies	multiple	oncogenic	components	of	the	
PI3K	pathway:	PDGFRA,	KIT,	and	a	regulator	of	PTEN	(miR‐26a‐2)	as	well	as	
CDK4	(Figure	2B).	To	assess	if	the	grade	IV	tumour	shows	increased	activation	of	
the	PI3K	pathway,	we	performed	immunohistochemistry	against	PDGFRA,	PTEN	
and	cKIT	in	the	grade	II	and	grade	IV	tumours	(Figure	3B).	We	found	increased	
levels	of	PDGFRA	(215/300	versus	93/300,	grade	IV	versus	grade	II)	and	cKIT	
(222/300	versus	31/300)	in	the	grade	IV	tumour,	but	no	difference	in	the	PTEN	
levels	(34/300	versus	23/300).	This	suggests	that	PTEN	is	deactivated	in	both	
the	grade	II	and	grade	IV	tumours,	but	that	the	PI3K	pathway	is	further	activated	
in	the	grade	IV	tumour,	likely	due	to	amplification	of	genes	encoded	within	the	
double	minute	chromosome.			
	
IDH1	driver	mutation	is	lost	at	recurrence		
Trunk	events	including	the	TP53	and	ATRX	mutations	and	PDGFRA/KIT,	
CDK4/miR‐26a‐2	focal	amplifications	along	with	the	grade	IV	private	mutation	
detected	in	AVIL	were	identified	at	high	frequency	in	the	recurrence	samples.	
Surprisingly,	the	IDH1	R132H	mutation	was	not	detected	in	the	recurrence	
samples	despite	being	clonal	in	the	grade	II	and	IV	lesions.	To	validate	this	
observation,	we	performed	digital	PCR	(dPCR)	on	IDH1	and	TP53	(using	TP53	as	
a	control).	We	confirmed	that	the	R132H	mutation	was	indeed	clonal	in	the	
grade	II	and	grade	IV	specimens	(found	in	approximately	42‐44%	of	DNA	
molecules,	Supplementary	File),	but	essentially	undetected	in	the	recurrence	
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11	
samples,	with	between	0.01%	and	0.1%	of	DNA	molecules	showing	the	mutation	
by	dPCR.	Conversely,	TP53	was	found	in	between	8%	and	12%	of	the	DNA	
molecules	(Supplementary	File),	consistent	with	clonal	presence	in	the	low‐
purity	recurrence	biopsies	(estimated	at	10‐15%	purity,	Supplementary	
Information).	It	is	likely	therefore	that	the	recurrence	has	experienced	loss	of	the	
mutated	IDH1	allele	and	retention	of	the	wild‐type	allele.		
	
A	recent	report	indicates	mutual	exclusivity	between	activation	of	the	PI3K	
pathway	and	IDH1	activity[20].	As	the	recurrence	demonstrated	increased	levels	
of	PDGFRA	and	KIT	amplification	encoded	on	the	DM,	activators	of	the	PI3K	
pathway,	we	addressed	whether	the	GBM	data	from	The	Cancer	Genome	Atlas	
(TCGA)[16]	supports	mutual	exclusivity	between	IDH1	R132H	mutation	and	
PDGFRA	and/or	KIT	amplification.	IDH1	and	TP53	mutations	are	enriched	in	the	
proneural	subtype[21].	Using	the	cBIO	portal[22],	we	identified	137	TCGA	GBM	
cases	classified	as	proneural	in	Brennan	et	al	[16],	with	both	sequence	and	copy	
number	data.	Of	these,	12	showed	the	R132H	mutation,	25	showed	dual	KIT	and	
PDGFRA	amplification,	and	10	showed	PDGFRA	amplification	only.	No	overlap	
between	cases	with	the	IDH1	R132H	mutation	and	KIT	and/or	PDGFRA	
amplification	was	detected,	indicating	mutual	exclusivity	between	these	
oncogenic	events	(P=	0.036,	Fisher’s	exact	test).	This	also	suggests	that	the	IDH1	
R132H	mutation	was	indeed	an	early	driver	event	that	was	subsequently	lost	
during	recurrence,	as	a	more	potent	polyoncogene‐oncomir	cluster	was	selected	
for	in	the	DM.		
	
An	analysis	of	TCGA	GBM	data	from	264	tumours	with	whole	exome	sequencing	
processed	by	Sanborn	et	al[9]	to	infer	DM	structures,	identified	four	samples,	of	
these	three	proneural,	with	amplifications	of	both	PDGFRA	and	CDK4,	possibly	
encoded	in	double	minute	chromosomes.	These	data	suggest	that	at	least	1.5%	
(4/264)	of	GBM	tumours	overall,	and	8%	(22/264)	of	the	proneural	subtype,	are	
driven	by	the	acquisition	of	such	a	macro‐evolutionary	event	typified	by	
PDGRA/CDK4/miR‐26a‐2	DMs.		
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Discussion	
This	study	is	the	first	report	of	a	multi‐region	longitudinal	WGS	of	a	glioblastoma	
from	diagnosis	to	death,	performed	specifically	with	the	intention	to	improve	
patient	outcome	by	the	application	of	tailored	therapy.	Unfortunately,	despite	
identifying	multiple	amplified	targetable	oncogenes	and	applying	targeted	
therapy,	disease	control	was	not	achieved,	and	the	patient	died	following	disease	
progression.		
	
To	our	knowledge,	this	is	the	first	description	of	a	loss	of	a	tier	1	clonal	driver	
event	(IDH1,	R132H)	during	disease	progression,	and	may	reflect	complex	
epistatic	relationships	between	tumour	somatic	events	and	the	selection	
pressure	of	therapy.	While	it	is	formally	possible	that	the	recurrence	evolved	
from	a	subclone	lacking	the	IDH1	mutation,	this	would	require	extensive	parallel	
evolution	since	the	majority	of	somatic	aberrations	were	shared	between	relapse	
and	the	grade	IV	region.	Rather,	the	progressive	enrichment	of	the	DMs	from	the	
grade	IV	to	recurrence	suggests	increased	oncogenic	potential	based	on	the	PI3K	
pathway.	With	the	waning	of	the	driver	IDH1	event	this	indicates	a	macro‐
evolutionary	switch	from	the	dominance	of	the	IDH1‐mutated	tumour	to	a	DM‐
driven	tumour	in	a	mutually	exclusive	context.	An	analysis	of	the	TCGA	data	also	
revealed	no	overlap	between	IDH1	R132H	mutations	and	PDGFRA/KIT	
amplification,	suggesting	that	high	level	PDGFRA/KIT	amplification	would	not	be	
favourable	with	an	existent	IDH1	R132H	mutation.	
	
These	findings	have	important	implications	for	precision	medicine,	suggesting	a	
targetable	clonal	driver	event	can	be	selectively	lost	during	the	disease	course,	
and	replaced	in	its	entirety	by	an	initially	low	frequency	event	in	the	primary	
tumour.	The	clonal	dominance	of	IDH1	driver	events	might	need	to	be	
considered	within	the	context	of	low	frequency	oncogenic	drivers	when	
examining	the	efficacy	of	therapeutics	targeting	IDH1	in	this	disease[23].	
Furthermore,	despite	rapid	WGS	at	recurrence	and	cancer	genome‐directed	
therapy,	imatinib	was	unable	to	control	the	disease.	Following	radiotherapy	and	
two	surgical	debulking	procedures,	it	is	unlikely	that	the	blood‐brain	barrier	was	
intact,	preventing	drug	penetration	into	the	central	nervous	system.	It	is	more	
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13	
likely	that	treatment	failure	was	a	consequence	of	the	evolution	of	the	poly‐
oncogene/oncomir	DM	targeting	the	PI3K	axis	at	multiple	nodal	points.		
	
Moreover,	our	results	highlight	the	profound	effects	of	cancer	cell	genome	
doubling,	resulting	in	accelerated	cancer	genome	evolution,	characterized	by	a	
tolerance	of	CIN	and	propagation	of	aneuploid	progeny	[15].	The	accelerated	CIN	
permitted	following	the	genome	doubling	event	in	the	grade	IV	region	of	the	
primary	tumour,	and	possibly	a	chromothripsis	event	on	chromosome	4,	
resulted	in	the	formation	and	subsequent	selection	of	a	highly	polyoncogene‐
oncomir	DM	encoding	miR‐26a‐2,	PDGFRA,	KIT	and	CDK4.		
	
MicroRNA	miR‐26a‐2	effectively	targets	PTEN[24].	Immunohistochemistry	
demonstrated	that	PTEN	expression	was	weak	or	absent	relative	to	stromal	cells	
in	both	the	grade	II	and	grade	IV	regions,	although	no	genomic	aberrations	were	
detected	at	the	PTEN	locus.	It	is	likely	therefore,	that	amplification	of	CDK4/miR‐
26a‐2	region,	either	encoded	within	the	DM	in	the	grade	IV	region	and	recurrent	
tumour	or	simply	due	to	amplification	as	observed	in	the	grade	II	specimen,	
directly	contributed	to	loss	of	PTEN	protein	expression.		
	
Taken	together,	these	observations	emphasise	the	complexity	of	signal	
transduction	cascades	activated	within	individual	tumours.	However,	it	is	
apparent	that	the	oncogenic	drivers	involved	in	GBM	pathogenesis	are	highly	
constrained	and	the	combination	of	these	events	involved	in	DMs	may	be	finite.	
There	is	an	unmet	need	to	enroll	patients	within	longitudinal	cohort	studies	to	
define	these	genetic	constraints	in	order	to	accelerate	our	understanding	of	GBM	
evolution	throughout	the	disease	course	and	optimise	therapeutic	opportunities	
in	this	disease.	
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FIGURES	LEGENDS	
	
Figure	1:	Timeline	and	clonal	structure.	
Timeline	of	the	patient’s	disease	from	diagnosis	to	death	(A)	timing	for	the	
temozolomide	(TMZ),	bevacizumab	(BEV)	and	imatinib	treatments.	Timeline	is	
not	drawn	to	scale	in	terms	of	length	of	time.	
A	Euler‐Venn	diagram	(B)	displaying	the	overlaps	of	non‐silent	and	silent	
mutations	in	the	joint	recurrence	cohort	and	the	grade	II	and	grade	IV	samples.	
A	mutation	spectrum	of	non‐synonymous	mutations	is	illustrated	as	an	heatmap	
of	the	detected	mutations	in	the	2	primary	tumour	sectors	and	in	the	joint	3	
recurrence	samples	(C).	Squares	coloured	in	yellow	represent	mutations	
detected	in	sub‐clonal	populations	in	the	specific	sector	while	red	squares	
represent	the	presence	of	the	mutation	in	the	clonal	population	of	the	respective	
sector.	
(D)	Two‐dimensional	clustering	of	mutations	in	the	grade	II	and	grade	IV	
specimens.	The	axis	correspond	the	cancer	cell	fraction	(CCF),	describing	the	
fraction	of	tumour	cells	carrying	the	mutation.	The	ordinate	corresponds	to	
grade	IV	specimen	and	the	abscissa	corresponds	to	grade	II	specimen.	Clusters	
present	on	the	upper	right	of	the	plot	correspond	to	clonal	mutations	present	in	
both	specimen;	clusters	located	in	the	upper	left	represent	clonal	mutations	
unique	of	the	grade	IV	and	the	bottom	right	correspond	to	clonal	mutations	
unique	of	the	grade	II	specimen.	
The	numbers	close	to	each	cluster	represent	the	number	of	non‐silent	and	
mutations	present	in	the	respective	cluster,	gene	symbols	represent	non‐
synonymous	mutation	present	in	the	cluster.		
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Figure	2:	Evolution	of	the	double	minute	
(A)	The	upper	panel	represents	the	genomic	segments	prior	to	the	DM	
formation,	with	genes	annotated	by	horizontal	lines.	The	lower	panel	contains	
circular	chromosome	plots	representing	the	double‐minute	models	for	the	grade	
IV	(G4)	and	recurrence	samples	(A1/A3),	with	validated	(and	shared)	
breakpoints	denoted	by	red	links	between	segments.	Light	grey	links	represent	
un‐validated	breakpoints	for	which	de	novo	contigs	could	be	assembled.	
Validated	breakpoints	are	illustrated	in	panels	B	and	C	
	
Figure	3	Evolution	a	GBM	tumor	to	recurrence	
(A)	Phylogenetic	tree	describing	the	evolution	of	the	tumour.	The	length	of	the	
branches	is	calculated	using	the	mutation	rate	as	described	in	the	method	
section.	The	recurrence	specimens	are	characterised	by	loss	of	the	IDH1	
mutation	and	by	the	further	evolution	of	the	double	minute.	Blue	dot	represents	
branching	of	Grade	II	and	Grade	IV	speciments,	orange	dot	represents	the	
genome‐doubling	event,	red	dot	represents	branching	of	recurrence	tumour	
from	the	Grade	IV	specimen.	Black	dots	represent	tumour	sampling.	For	IDH1,	
mutant	allele	frequency	detected	by	dPCR	is	indicated	in	parenthesis	(B)	
Immunohistochemistry	showing	increased	expression	of	cKIT	and	PDGFRA	in	the	
grade	IV	component	of	the	primary	tumour	relative	to	grade	II.	PTEN	is	highly	
expressed	in	the	proliferating	vessels	of	both	the	grade	II	and	IV	primary	tumour	
sectors	but	the	neoplastic	astrocytes	are	largely	negative.	
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